The Serum Institute of India is reportedly in discussions with DEK Vaccines Limited in Ghana to fill-finish and produce the R21 malaria vaccine, which was approved by Ghana earlier this month. The approval of the R21 malaria vaccine by Ghana and Nigeria is uncommon because the final-stage trial results have not been released, and the World Health Organization (WHO) is still evaluating the vaccine's safety and efficacy.
Additionally, fill-finishing is a critical stage in the manufacturing and packaging process. According to Phionah Atuhebwe, a vaccines introduction officer at the WHO, the regulators of Ghana and Nigeria were not hasty in approving the R21 vaccine as they were able to evaluate the data as it became available.Mosquito-borne malaria kills over 600,000 people annually, mainly African babies and children. Oxford's R21 malaria vaccine is the second vaccine to be approved for use against malaria, and it has a partnership with Serum Institute of India to manufacture up to 200 million doses of the vaccine every year.
© Copyright 2023. All Rights Reserved Powered by Vygr Media.
